| Product Code: ETC13117570 | Publication Date: Apr 2025 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sachin Kumar Rai | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 |
In 2024, Belgium continued to heavily rely on imports for pneumococcal vaccines, with major suppliers including the USA, Austria, Netherlands, Hungary, and the UK. Despite a high concentration of imports, the market experienced a significant decline in growth rate from 2023 to 2024. However, the overall compound annual growth rate (CAGR) from 2020 to 2024 remained remarkably strong at 39.8%, indicating sustained demand for pneumococcal vaccines in the Belgian market. This data suggests that while there may have been a temporary setback, the long-term outlook for pneumococcal vaccine imports in Belgium remains positive.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Belgium Pneumococcal Vaccines Market Overview |
3.1 Belgium Country Macro Economic Indicators |
3.2 Belgium Pneumococcal Vaccines Market Revenues & Volume, 2021 & 2031F |
3.3 Belgium Pneumococcal Vaccines Market - Industry Life Cycle |
3.4 Belgium Pneumococcal Vaccines Market - Porter's Five Forces |
3.5 Belgium Pneumococcal Vaccines Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Belgium Pneumococcal Vaccines Market Revenues & Volume Share, By Vaccine Technology, 2021 & 2031F |
3.7 Belgium Pneumococcal Vaccines Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 Belgium Pneumococcal Vaccines Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 Belgium Pneumococcal Vaccines Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about the importance of vaccinations in Belgium |
4.2.2 Government initiatives promoting vaccination programs |
4.2.3 Rising prevalence of pneumococcal diseases in Belgium |
4.3 Market Restraints |
4.3.1 High cost of pneumococcal vaccines |
4.3.2 Limited access to vaccines in rural areas |
4.3.3 Vaccine hesitancy among certain demographics in Belgium |
5 Belgium Pneumococcal Vaccines Market Trends |
6 Belgium Pneumococcal Vaccines Market, By Types |
6.1 Belgium Pneumococcal Vaccines Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Type, 2021 - 2031F |
6.1.3 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Conjugate, 2021 - 2031F |
6.1.4 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Polysaccharide, 2021 - 2031F |
6.1.5 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Combination, 2021 - 2031F |
6.1.6 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Live Attenuated, 2021 - 2031F |
6.1.7 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Others, 2021 - 2031F |
6.2 Belgium Pneumococcal Vaccines Market, By Vaccine Technology |
6.2.1 Overview and Analysis |
6.2.2 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Protein-based, 2021 - 2031F |
6.2.3 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Recombinant, 2021 - 2031F |
6.2.4 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Inactivated, 2021 - 2031F |
6.2.5 Belgium Pneumococcal Vaccines Market Revenues & Volume, By mRNA-based, 2021 - 2031F |
6.2.6 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Others, 2021 - 2031F |
6.3 Belgium Pneumococcal Vaccines Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.3.3 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.3.4 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Government, 2021 - 2031F |
6.3.5 Belgium Pneumococcal Vaccines Market Revenues & Volume, By NGOs, 2021 - 2031F |
6.3.6 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Others, 2021 - 2031F |
6.4 Belgium Pneumococcal Vaccines Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Immunization, 2021 - 2031F |
6.4.3 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Disease Prevention, 2021 - 2031F |
6.4.4 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Pediatric Vaccination, 2021 - 2031F |
6.4.5 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Elderly Care, 2021 - 2031F |
6.4.6 Belgium Pneumococcal Vaccines Market Revenues & Volume, By Others, 2021 - 2031F |
7 Belgium Pneumococcal Vaccines Market Import-Export Trade Statistics |
7.1 Belgium Pneumococcal Vaccines Market Export to Major Countries |
7.2 Belgium Pneumococcal Vaccines Market Imports from Major Countries |
8 Belgium Pneumococcal Vaccines Market Key Performance Indicators |
8.1 Percentage increase in vaccination coverage rates in Belgium |
8.2 Number of government-funded vaccination campaigns |
8.3 Rate of reported pneumococcal disease cases in Belgium |
9 Belgium Pneumococcal Vaccines Market - Opportunity Assessment |
9.1 Belgium Pneumococcal Vaccines Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Belgium Pneumococcal Vaccines Market Opportunity Assessment, By Vaccine Technology, 2021 & 2031F |
9.3 Belgium Pneumococcal Vaccines Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 Belgium Pneumococcal Vaccines Market Opportunity Assessment, By Application, 2021 & 2031F |
10 Belgium Pneumococcal Vaccines Market - Competitive Landscape |
10.1 Belgium Pneumococcal Vaccines Market Revenue Share, By Companies, 2024 |
10.2 Belgium Pneumococcal Vaccines Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here